Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis

Lenalidomide and dexamethasone (Rd)-based triplets, in particular carfilzomib-Rd (KRd) and daratumumab-Rd (DaraRd), represent a standard of care in lenalidomide-sensitive multiple myeloma (MM) patients in first relapse. Meta-analysis of randomized clinical trials (RCT), suggested better outcome with...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Mangiacavalli, Silvia, Cartia, Claudio Salvatore, Galli, Monica, Pezzatti, Sara, Belotti, Angelo, Fazio, Francesca, Mina, Roberto, Marcatti, Magda, Cafro, Anna, Zambello, Renato, Paris, Laura, Barilà, Gregorio, Olivares, Cecilia, Pompa, Alessandra, Mazza, Rita, Farina, Francesca, Soldarini, Martina, Benvenuti, Pietro, Pagani, Giuseppina, Palumbo, Michele, Masoni, Valeria, Ferretti, Virginia Valeria, Klersy, Catherine, Arcaini1, Luca, Petrucci, Maria Teresa
Formatua: Online Artikulua Texto
Hizkuntza:English
Argitaratua: Fondazione Ferrata Storti 2022
Gaiak:
Article - Plasma Cell Disorders
Sarrera elektronikoa:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973473/
https://www.ncbi.nlm.nih.gov/pubmed/36200419
http://dx.doi.org/10.3324/haematol.2022.281342

Antzeko izenburuak